The AI healthcare stories that get the most attention are often the most speculative: AI that will replace doctors, AI that will cure cancer, AI that misdiagnosed a patient. The quieter, more documented story is that AI has been improving specific, narrow medical tasks with measurable accuracy for several years — and those improvements are beginning to reach clinical practice. Here is what is actually happening in 2026.
Radiology: Where AI Delivers Most Consistently
Medical imaging analysis is a pattern recognition task — exactly what deep learning systems are built for. The advances here are the most mature and the most rigorously validated.
Diabetic retinopathy screening: Google’s DeepMind and other systems detect diabetic retinopathy in retinal photographs with sensitivity matching or exceeding specialist ophthalmologists. This matters because there are 537 million diabetics globally and a severe shortage of ophthalmologists in lower-income countries. AI screening systems are now deployed in India, Thailand, and parts of Africa to extend specialist access to populations that previously had none.
Chest X-ray analysis: CheXpert (Stanford) and similar systems detect 14 types of pathological conditions in chest X-rays with performance comparable to radiologists. In 2025, NHS England began piloting AI triage of chest X-ray queues to prioritise urgent cases — reducing the time from scan to urgent action in cancer-suspicious cases.
Lung cancer screening: Google’s LYNA system detects lymph node metastases in pathology slides with 99% accuracy in controlled studies. Mayo Clinic has deployed AI-assisted colonoscopy detection tools that have measurably improved polyp detection rates in clinical use.
Pathology: The Next Frontier
Pathology — the analysis of tissue samples — has been slower to adopt AI than radiology, partly because the digitisation of pathology labs is more recent. But progress in 2025-2026 has been significant.
Paige Prostate (FDA-cleared in 2021) and similar AI pathology tools now assist pathologists in detecting prostate cancer in biopsy samples. Studies show that AI assistance increases sensitivity (catching more true positives) while reducing the time pathologists spend on negative slides — allowing them to focus attention where it matters most.
Genomics and Precision Medicine
The sequencing of a human genome costs under $100 in 2026 (down from $100 million in 2001). The challenge is no longer sequencing — it is interpretation. AI tools like DeepVariant (Google) and Illumina’s DRAGEN system identify genetic variants from sequencing data faster and more accurately than previous methods.
More clinically significant is the use of AI to match patients to treatments based on their genomic profile. Several cancer centres now use AI-driven tumour profiling to recommend targeted therapies for specific genetic mutations — a personalised approach that traditional population-level clinical trial data cannot support.
What Is Not Yet Ready for Primetime
For every validated AI advance, there are multiple AI healthcare products making claims not yet supported by rigorous evidence:
- General diagnostic chatbots that have not been validated on diverse patient populations
- Mental health prediction tools claiming to identify suicidal ideation from voice or text with insufficient validation
- Wellness apps using AI labels to claim medical-grade insights from consumer hardware
The standard for clinical AI tools should be prospective validation on diverse populations, peer-reviewed publication, and regulatory clearance. Many commercially available products have none of these.
The Access Question
The most important question about AI in healthcare is not “can it detect disease?” — increasingly it can. The question is whether these tools will reach the patients who need them most. The history of medical technology is largely a history of innovations that benefited wealthy populations first and lower-income populations a generation later. AI health tools have the potential to break this pattern — or to accelerate it.
Key Takeaway: AI is making genuine, validated progress in radiology, pathology, and genomics. These are narrow, high-precision tasks where AI’s pattern recognition excels. The story in 2026 is deployment and access — getting validated tools to the patients who would benefit most from them.
Be the first to respond